Evaxion Biotech A/S - ADR

EVAX | $4.2 -0.47% -0.48% 31K

(0.0% 1d) (39.3% 1m) (212.6% 1y) (0.0% 2d) (3.4% 3d) (2.9% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 21,903,231
https://www.evaxion-biotech.com
Sec Filling | Patents | 2020 employees

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.

vaccine cancer immunotherapy infectious disease injection batteries skin

add to watch list Paper trade email alert is off

Press-releases

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing

| 3.69% | O: 0.25% H: 0.0% C: 0.0%
evx-01 first vaccine cancer trial

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing

| 32.29% | O: 6.58% H: 14.71% C: 14.12%
vaccine infection results

Evaxion Announces Business Update and Full Year 2023 Financial Results
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing

| 34.82% | O: 0.0% H: 0.0% C: -4.15%
business year update financial results

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing

| 37.01% | O: -2.6% H: 6.67% C: 2.33%
day potential platform

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
Published: 2024-02-29 (Crawled : 12:30) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing

| 15.3% | O: 0.55% H: 2.99% C: -2.17%
day technology

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing

| 4.2% | O: 9.14% H: 1.81% C: -9.73%
vaccine ongoing collaboration

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
Published: 2024-02-07 (Crawled : 13:30) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing

| -6.22% | O: 0.0% H: 2.22% C: -4.89%
nasdaq

Evaxion Announces Closing of $15 Million Public Offering
Published: 2024-02-06 (Crawled : 13:30) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing

| -0.71% | O: 4.24% H: 7.0% C: 1.58%
million offering

Evaxion Biotech Announces Pricing of $15 Million Public Offering
Published: 2024-02-01 (Crawled : 14:00) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K

Manufacturing